Table 1 Patient characteristics
Responder, n = 14 | Non-responder, n = 21 | |
|---|---|---|
Sex | ||
F | 5 (36%) | 9 (43%) |
M | 9 (64%) | 12 (57%) |
Stage at diagnosis | ||
I | 4 (29%) | 8 (38%) |
II | 3 (21%) | 3 (14%) |
III | 5 (36%) | 7 (33%) |
IV | 2 (14%) | 3 (14%) |
Histology | ||
Adenocarcinoma | 12 (86%) | 12 (57%) |
Squamous Cell Carcinoma | 2 (14%) | 9 (43%) |
IO treatment | ||
DURVALUMAB | 1 (7.1%) | 0 (0%) |
NIVOLUMAB | 10 (71%) | 18 (86%) |
PEMBROLIZUMAB | 3 (21%) | 3 (14%) |
Status | ||
Alive | 13 (93%) | 8 (38%) |
Deceased | 1 (7.1%) | 13 (62%) |